Longeveron (LGVN) Stock Forecast, Price & News

Longeveron (NASDAQ:LGVN) Frequently Asked Questions

Is Longeveron a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Longeveron in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Longeveron stock.
View analyst ratings for Longeveron or view top-rated stocks.

Are investors shorting Longeveron?

Longeveron saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 315,100 shares, a drop of 52.2% from the April 15th total of 658,700 shares. Based on an average trading volume of 5,010,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 7.0% of the shares of the stock are short sold.
View Longeveron's Short Interest.

When is Longeveron's next earnings date?

Longeveron is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Longeveron.

How were Longeveron's earnings last quarter?

Longeveron Inc. (NASDAQ:LGVN) announced its earnings results on Friday, May, 13th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. Longeveron had a negative trailing twelve-month return on equity of 61.98% and a negative net margin of 1,341.85%. During the same period last year, the firm posted ($0.18) earnings per share.
View Longeveron's earnings history.

What price target have analysts set for LGVN?

2 Wall Street analysts have issued 12 month price objectives for Longeveron's stock. Their forecasts range from $14.00 to $14.00. On average, they expect Longeveron's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 54.5% from the stock's current price.
View analysts' price targets for Longeveron or view top-rated stocks among Wall Street analysts.

Who are Longeveron's key executives?

Longeveron's management team includes the following people:

• Dr. Joshua Michael Hare FACC, M.D., Co-Founder, Chief Science Officer & Chairman (Age 59, Pay $437.81k)
• Mr. Geoff Green M.B.A., Chief Exec. Officer (Age 48, Pay $560.94k) (LinkedIn Profile)
• Mr. James Clavijo CPA, CFO & Treasurer (Age 56, Pay $481.07k) (LinkedIn Profile)
• Mr. Paul T. Lehr J.D., International Exec. Director, Gen. Counsel & Sec. (Age 54, Pay $465.25k) (LinkedIn Profile)
• Dr. Dan Gincel Ph.D., Sr. VP of Strategic Collaborations & Scientific Affairs (Age 51)
• Dr. Kwan-Hong Christopher Min M.D., Ph.D., Chief Medical Officer (Age 55)

Who are some of Longeveron's key competitors?

Some companies that are related to Longeveron include Mirum Pharmaceuticals (MIRM), Chinook Therapeutics (KDNY), Evolus (EOLS), Avid Bioservices (CDMO), Deciphera Pharmaceuticals (DCPH), Acerus Pharmaceuticals (TRLPF), IGM Biosciences (IGMS), Nektar Therapeutics (NKTR), Organogenesis (ORGO), Catalyst Pharmaceuticals (CPRX), Merus (MRUS), Erasca (ERAS), Rocket Pharmaceuticals (RCKT), DICE Therapeutics (DICE) and Relmada Therapeutics (RLMD).
View all of LGVN's competitors.

When did Longeveron IPO?

(LGVN) raised $30 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 2,700,000 shares at $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. acted as the underwriters for the IPO.

What is Longeveron's stock symbol?

Longeveron trades on the NASDAQ under the ticker symbol "LGVN."

Who are Longeveron's major shareholders?

Longeveron's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.55%), Sassicaia Capital Advisers LLC (0.49%), Citigroup Inc. (0.35%), Gamco Investors INC. ET AL (0.16%), Gamco Investors INC. ET AL (0.16%) and Anson Funds Management LP (0.10%). Company insiders that own Longeveron stock include Geoff Green, James Clavijo, Joshua Hare, Paul T Lehr and Rock Soffer.
View institutional ownership trends for Longeveron.

Which major investors are buying Longeveron stock?

LGVN stock was bought by a variety of institutional investors in the last quarter, including Sassicaia Capital Advisers LLC, Citigroup Inc., Gamco Investors INC. ET AL, Gamco Investors INC. ET AL, Anson Funds Management LP, and Vanguard Group Inc.. Company insiders that have bought Longeveron stock in the last two years include Geoff Green, James Clavijo, Joshua Hare, Paul T Lehr, and Rock Soffer.
View insider buying and selling activity for Longeveron or or view top insider-buying stocks.

How do I buy shares of Longeveron?

Shares of LGVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Longeveron's stock price today?

One share of LGVN stock can currently be purchased for approximately $9.06.

How much money does Longeveron make?

Longeveron has a market capitalization of $189.44 million and generates $1.31 million in revenue each year. The company earns $-17.05 million in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does Longeveron have?

Longeveron employs 18 workers across the globe.

What is Longeveron's official website?

The official website for Longeveron is www.longeveron.com.

How can I contact Longeveron?

Longeveron's mailing address is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. The company can be reached via phone at 305-909-0840 or via email at [email protected].